The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: A Children’s Oncology Group (COG) report.
Matthew John Barth
No relevant relationships to disclose
Stanton Goldman
No relevant relationships to disclose
Lynette Smith
No relevant relationships to disclose
Sherrie L Perkins
No relevant relationships to disclose
Bruce Shiramizu
No relevant relationships to disclose
Thomas G. Gross
Consultant or Advisory Role - Boehringer Ingelheim; Genentech/Roche; Janssen Biotech
Lauren Harrison
No relevant relationships to disclose
Warren Sanger
No relevant relationships to disclose
Mark B Geyer
No relevant relationships to disclose
Lisa B. Giulino
No relevant relationships to disclose
Mitchell S. Cairo
No relevant relationships to disclose